Genentech’s Lucentis BLA Will Not Include Data Supporting Dosing Advantage
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's decision to deny Genentech fast-track status for Lucentis (ranibizumab) means that the initial submission for the wet age-related macular degeneration therapy, slated for December, will not include data supporting a dosing advantage